We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target
News

ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target

ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target
News

ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IL-13 is an immune regulatory cytokine and IL-13Rα2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. IL-13Rα2 is an important target of ImmunoCellular’s lead product candidate, ICT-107, a dendritic cell vaccine directed against glioblastoma antigens and cancer stem cells, as well as ICT-140, a dendritic cell vaccine to treat ovarian cancer.

“We believe that this issued patent will complement and extend the broad intellectual property protection we have established for two of our company’s key assets, ICT-107 and ICT-140, and represents a valuable addition to our patent estate,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “IL-13Rα2 is a tumor-associated antigen present in the majority of brain cancers, and we believe that using an immunotherapeutic vaccine that targets this and other specific antigens as well as cancer stem cells to stimulate an immune response represents a promising anticancer approach.”

The IL-13Rα2 patent was issued to The Penn State Research Foundation, the technology transfer agent for The Pennsylvania State University, and is licensed to Targepeutics, Inc. ImmunoCellular is a sub-licensee of the patent.

Advertisement